Showing 71 - 80 of 8,590
Background:Background: In 2005, the French Government implemented a new way of financing high-cost drugs for hospitals in order to promote innovation. Such drugs are gathered on a positive list, established by the Ministry of Health, with a reimbursement price cap. Hospitals still negotiate with...
Persistent link: https://www.econbiz.de/10011005079
As antiretroviral treatment (ART) for HIV/AIDS is scaled up globally, information on per-person costs is critical to improve efficiency in service delivery and to maximize coverage and health impact. The objective of this study was to review studies on unit costs for delivery of adult and...
Persistent link: https://www.econbiz.de/10011005080
Background: Recent National Institute for Health and Clinical Excellence (NICE) guidance recommended that when traditional NSAIDs or cyclo-oxygenase (COX)-2 selective inhibitors are used by people with osteoarthritis (OA), they should be prescribed along with a proton pump inhibitor (PPI)....
Persistent link: https://www.econbiz.de/10011005081
Persistent link: https://www.econbiz.de/10011005082
Objectives:Objectives: Our objective was to evaluate the potential usefulness of the Kano conceptual model to assess expectations of patients and neurologists in Spain regarding symptomatic migraine treatment. Abstract: Methods:Methods: We performed a multicenter, cross-sectional study in adult...
Persistent link: https://www.econbiz.de/10011005083
Persistent link: https://www.econbiz.de/10011005084
Background: Shared decision making is the process in which a healthcare choice is made jointly by the health professional and the patient. Little is known about what patients view as effective or ineffective strategies to implement shared decision making in routine clinical practice. Objective:...
Persistent link: https://www.econbiz.de/10011005085
Background: Côte d'Ivoire, a West African country, has decided to set up a formulary as part of its universal health insurance (UHI) program. One of its goals will be to facilitate access to safe and efficacious drugs. To guarantee transparency throughout the formulary listing process, it is...
Persistent link: https://www.econbiz.de/10011005086
Background: Low-dose acetylsalicylic acid (ASA; 75-325 mg) is a mainstay of therapy for patients at high risk of cardiovascular (CV) events. However, in some patients, such treatment is associated with upper gastrointestinal (GI) adverse effects, e.g. dyspeptic symptoms, peptic ulceration, and...
Persistent link: https://www.econbiz.de/10011005087
Persistent link: https://www.econbiz.de/10010923399